SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Summary

This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam Radiation Therapy (SBRT) * Surgery

Timeline

Start

2021-06-18

Primary completion

2026-04-29

Completion

2027-04-29

Drugs

Indications